Incorporating survival data, we anticipated that approximately 60% would have died of their disease by 2018.24 Previous literature indicates that 15% of Australian patients with HGNMOC carry a pathogenic germline BRCA1/2 variant.8 We therefore estimated that in 2018, approximately 1,100 BRCA1/2 pathogenic germline variant carriers exist among untested, deceased patients with ovarian cancer in Australia. This evidence concerns the gene BRCA1 and ovarian carcinoma.